Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04594707
Other study ID # WA42294
Secondary ID 2020-001429-30
Status Terminated
Phase Phase 3
First received
Last updated
Start date August 30, 2021
Est. completion date February 10, 2023

Study information

Verified date March 2023
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).


Description:

This study is being conducted for the treatment of eligible participants who have taken part in Study PRM-151-202 and received the open-label study drug or completed the Phase III Study WA42293 with PRM-151. Participants who have discontinued treatment from or have completed Study WA42293 and do not want to receive PRM-151 in this study, will be invited to enroll in survival follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 117
Est. completion date February 10, 2023
Est. primary completion date February 10, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Taken part in either of the prior PRM-151 studies: PRM-151-202 or WA42293. - For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception. - For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm. Exclusion Criteria: - Acute respiratory or systemic bacterial, viral, or fungal infection at the first visit of the OLE, or within 2 weeks of the first visit for patients joining Cohort A (from Study PRM-151-202). - History of smoking within 3 months prior to the first visit in the OLE. - History of alcohol or substance use disorder within 2 years prior to the first visit of the OLE or known or suspected active alcohol or substance-use disorder. - History of severe allergic reaction or anaphylactic reaction to PRM-151. - Clinically significant abnormality on ECG during eligibility assessment that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant. - Prolonged corrected QT interval > 450 ms (for men) or > 470 ms (for women) based on the Fridericia correction formula. - Clinically significant laboratory test abnormalities (hematology, serumchemistry, and urinalysis) that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant.

Study Design


Intervention

Drug:
PRM-151 (Zinpentraxin Alfa)
Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks. Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo.

Locations

Country Name City State
Argentina Fundacion Respirar (Centro Medico Dra. De Salvo) Ciudad Autonoma Buenos Aires
Argentina Hospital Britanico de Buenos Aires Ciudad Autonoma Buenos Aires
Argentina Instituto de Medicina Respiratoria, IMeR; Clinic/Outpatient Facility Córdoba
Argentina Hospital Universitario Austral Derqui-Pilar
Argentina Centro Medico de Enfermedades Respiratorias (CEMER) Florida, Buenos Aires
Argentina Centro de estudios respiratorios Mar Del Plata
Argentina Fundacion Scherbovsky Mendoza
Argentina INSARES Mendoza, Mendoza City
Argentina Instituto Medico de la Fundacion Estudios Clinicos Rosario
Argentina Investigaciones en Patologias Respiratorias San Miguel de Tucuman
Australia Cairns Base Hospital; Cancer Care Centre Cairns Queensland
Australia Royal Prince Alfred Hospital Camperdown New South Wales
Australia Monash Medical Centre; Medicine Melbourne Victoria
Australia Lung Research Queensland Nundah Queensland
Australia The Alfred Hospital Prahan Victoria
Australia Princess Alexandra Hospital Woolloongabba Queensland
Belgium ULB Hôpital Erasme Brussels
Belgium Cliniques Universitaires Saint-Luc; Pharmacy Bruxelles
Belgium UZ Leuven Leuven
Belgium C. H. U. Sart-Tilman; Laboratory Liège
Belgium CHU UCL Namur / site Godinne Yvoir
Canada Kelowna Respiratory and Allergy Clinic Kelowna British Columbia
Canada The Rhema Research Institute Owen Sound Ontario
Canada Synergy Respiratory Care Sherwood Park Alberta
Canada C.I.C. Mauricie Trois-Rivières Quebec
Canada Dr. Syed Anees Medicine Profession Corporation Windsor Ontario
China Peking Union Medical College Hospital; Pharmacy Beijing City
China Beijing Friendship Hospital Affiliated of Capital University of Medical Science Beijing Shi
China The Second Xiangya Hospital of Central South University Changsha
China The Third Xiangya Hospital Of Central South University Changsha
China Shengjing Hospital of China Medical University ShenYang
China Hebei Medical University - The Second Hospital Shijiazhuang City
China Tianjin Medical University General Hospital Tianjin
China Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan City
China Wuxi People's Hospital Wuxi
China The First Affiliated Hospital of Zhengzhou University Zhengzhou
Czechia Fakultni nemocnice Brno Brno
Czechia Fakultni Nemocnice; Interni Klinika - odd. Invazivni Kardiologie Hradec Kralove
Czechia Thomayerova nemocnice; Lekarna - pavilon H Praha 4
Czechia Krajska nemocnice T. Bati a.s.; Neurologicke oddeleni Zlin
Denmark Gentofte Hospital Hellerup
Denmark Odense Universitetshospital Odense C
France Hopital Avicenne Bobigny
France Centre Hospitalier Regional Universitaire de Brest - Hopital de la Cavale Blanche Brest
France Hopital Louis Pradel Bron
France CHU Hopitaux de Bordeaux CHU Hopitaux De Bordeaux
France CHU Dijon Bourgogne Hôpital François Mitterand Dijon
France CHU de Grenoble - Hôpital André Michallon; Pole Pharmacie La Tronche
France Centre Hospitalier Regional Universitaire de Lille Lille
France Servie de Pneumologie et centre de Transplantation Pulmonaire Marseille
France CHU Nice - Hôpital Pasteur 2 Nice
France Hopital Bichat Claude Bernard; Hepatologie Gastro Enterologie Paris
France Centre Hospitalier Universitaire de Reims; l'Hopital Maison Blanche Reims
France Centre Hospitalier Universitaire de Rennes Rennes
France CHU Tours - Hôpital Bretonneau Tours
Germany Evang. Lungenklinik Berlin Klinik für Pneumologie Berlin
Germany Thoraxklinik-Heidelberg gGmbH; Apotheke der Thoraxklinik Heidelberg
Germany Lungenfachklinik Immenhausen Immenhausen
Germany Praxis für Pneumologie Dr. Silke Mronga & Dr. Lukas Jerrentrup Marburg
Germany Lungenklinik Münnerstadt, Thoraxzentrum Bezirk Unterfranken Münnerstadt
Germany Krankenhaus Bethanien gGmbH Solingen
Greece Evangelismos Hospital; Endocrinology, Diabetes & Metabolism Athens
Greece Attikon University General Hospital Chaidari
Greece University General Hospital of Heraklion Herakleion
Greece University Hospital of Ioannina; Pulmonology Department Ioannina
Greece Athens Medical Center Marousi
Greece University of Thessaly Faculty of Medicine Mezourlo
Greece University General Hospital of Patras Patras
Greece "General hospital of Chest Diseases ""Sotiria"", 7th Pulmonary Clinic " Sotiria Athens
Greece General Hospital of Thessaloniki G. Papanikolaou Thessaloniki
Hong Kong Prince of Wales Hospital; Dept. of Medicine & Therapeutics Hong Kong
Hong Kong The University of Hong Kong; Queen Mary Hospital Hong Kong
Hungary Semmelweis University Budapest
Hungary Debreceni Egyetem Debrecen
Hungary Markusovszky Egyetemi Oktatokorhaz ; SZEMESZET Szombathely
Hungary Szent Borbala Korhaz Tatabánya
Hungary Tudogyogyintezet Torokbalint; Onkologiai és Jarobeteg Centrum Törökbálint
Israel Barzilai Medical Center; Neurology Department Ashkelon
Israel Shamir medical center Be'er Ya'akov
Israel Ben-Gurion University of the Negev - Soroka University Medical Center - Pulmonology Institute Beer sheva
Israel Rambam Health Care Campus Haifa
Israel Edith Wolfson Medical Center Holon
Israel Hadassah Medical Center Jerusalem
Israel Shaare Zedek Medical Center Jerusalem
Israel Meir Medical Center Kfar- Saba
Israel Rabin Medical Center Petach Tiqwa
Israel The Chaim Sheba Medical Center Ramat Gan
Israel Kaplan Medical Center Rehovot
Israel Tel Aviv Sourasky Medical Center; Department of Neurology Tel Aviv
Italy Azienda Ospedaliera Papa Giovanni XXIII Bergamo Abruzzo
Italy Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele Catania Sicilia
Italy AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2 Firenze Toscana
Italy Policlinico Riuniti di Foggia - Department of Medical and Surgical Sciences - University of Foggia Foggia Puglia
Italy Ospedale Morgagni Pierantoni; Patologia clinica Forlì Emilia-Romagna
Italy Asst Santi Paolo E Carlo Milano Lombardia
Italy Ospedale San Giuseppe; U.O. di Pneumologia Milano Lombardia
Italy A.O.U. Policlinico di Modena Modena Emilia-Romagna
Italy Ospedale San Gerardo Monza Lombardia
Italy "AZIENDA OSPEDALIERA DEI COLLI Monaldi-Cotugno-CTO - Pneumologia " Napoli Campania
Italy Azienda Ospedaliera Universitaria Federico II Napoli Campania
Italy Azienda Ospedale Universita Di Padova; Divisione Clinicizzata Di Nefrologia 1 Padova Veneto
Italy Az. Osp. Univ. P. Giaccone; UOC di Pneumologia Palermo Sicilia
Italy Ismett Istituto Mediterraneo Trapianti E Terapie Alta Specializzazione;Pneumologia Palermo Sicilia
Italy Fondazione IRCCS Policlinico San Matteo Divisione di EmatologiaDipartimento di Onco-Ematologia Pavia Lombardia
Italy Fondazione Policlinico Universitario A Gemelli; Servizio di Farmacia Rome Lazio
Italy Policlinico Tor Vergata - U.O.C. Malattie Apparato Respiratorio Rome Lazio
Italy A.O.U. Sassari; Dip. Medicina Clinica e Sperimentale Sassari Sardegna
Italy A.O. Univ. Senese Policlinico S. Maria alle Scotte; Dip. Medicina clinica e Scienze Immunologiche Siena Toscana
Italy University of Padova Ca' Foncello Hospital Immunologic & Respiratory Rare Diseases Center Treviso Veneto
Japan Nagoya University Hospital Aichi
Japan Chiba University Hospital Chiba
Japan Fukuoka University Hospital Fukuoka
Japan National Hospital Organization Kyushu Medical Center Fukuoka
Japan Kobe City Medical Center General Hospital Hyogo
Japan National Hospital Organization Himeji Medical Center Hyogo
Japan Kameda Medical Center Kamogawa
Japan Kanagawa Cardiovascular and Respiratory Center Kanagawa
Japan Nippon Medical School Musashi Kosugi Hospital Kawasaki-Shi
Japan Saiseikai Kumamoto Hospital Kumamoto-Shi
Japan Nagasaki University Hospital Nagasaki
Japan National Hospital Organization Ibarakihigashi National Hospital; Center for Clinical Research Naka-gun
Japan Kurashiki Central Hospital Okayama
Japan National Hospital Organization Kinki-Chuo Chest Medical Center Sakai-shi
Japan Tosei General Hospital Seto-shi
Japan Tenri Hospital Tenri-Shi
Japan Jichi Medical University Hospital Tochigi
Japan Tokushima University Hospital Tokushima
Japan Center Hospital of the National Center for Global Health and Medicine Tokyo
Japan Tokyo Medical Ando Dentaluni Hospital Faculty of Medicine; Surgical Oncology Tokyo
Korea, Republic of The Catholic University of Korea Bucheon St. Mary's Hospital Gyeonggi-do
Korea, Republic of Gacheon University Gil Medical Center Namdong-gu
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Korea University Guro Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital (SNUH) - Medical Oncology Center Seoul
Korea, Republic of Soonchunhyang University Hospital Seoul
Korea, Republic of The Catholic University of Korea Yeouido St. Mary's Hospital; Hematology-Oncology Seoul
Mexico Unidad de Investigacion CIMA SC Chihuahua
Mexico Centro Respiratorio de México Mexico
Mexico INER- Instituto Nacional de Enfermedades Respiratorias"Ismae Mexico
Mexico CICC Morelia Morelia
Mexico Unidad Médica para la Salud Integral UMSI San Nicolás de Los Garza Nuevo LEON
Netherlands Sint Antonius Ziekenhuis, locatie Nieuwegein Nieuwegein
Netherlands Erasmus Medisch Centrum Rotterdam
New Zealand Auckland City Hospital Auckland
New Zealand NZ Respiratory & Sleep Institute Auckland
New Zealand University of Otago, Christchurch Christchurch
New Zealand Waikato Hospital; Gastro Research Hamilton
New Zealand Tauranga Hospital Tauranga
Norway Helse Bergen HF Haukeland universitetssykehus; Hudavdelingen Bergen
Norway Akershus universitetssykehus Lørenskog
Norway Oslo University Hospital HF, Rikshospitalet Oslo
Poland Centrum Medycyny Oddechowej Mroz sp. j. Bia?ystok
Poland Nasz Lekarz Osrodek Badan Klinicznych Bydgoszcz
Poland SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi Lodz
Portugal Hospital de Braga; Centro Clínico Académico (Piso 1, Ala E) Braga
Portugal Centro Hospitalar do Alto Ave; EPE Guimarães
Portugal Centro Hospitalar Universitario Lisboa Norte - Hospital Pulido Valente Lisboa
Portugal CHVNG/E_Unidade 1; Servico de Pneumologia Vila Nova de Gaia
Singapore National University Hospital Singapore
Singapore Singapore General Hospital Singapore
Singapore Tan Tock Seng Hospital; Oncology Singapore
South Africa University of Cape Town Lung Institute; Lung Clinical Research Cape Town
South Africa Vergelegen Medi-Clinic Somerset West
Spain Hospital Clinic I Provincial Barcelona
Spain Hospital de la Santa Creu i Sant Pau; Servicio de Neumologia Barcelona
Spain Hospital Germans Trias i Pujol Barcelona
Spain Hospital Universitario del Henares Coslada Madrid
Spain Hospital Galdakao-Usansolo Galdakao Vizcaya
Spain Hospital Virgen de las Nieves; Servicio de Neumologia Granada
Spain Hospital Universitario de Bellvitge Hospitalet de Llobregat Barcelona
Spain Clinica Universidad de Navarra ; Servicio de Farmacia Madrid
Spain Fundacion Jimenez Diaz-UTE Madrid
Spain Hosp. Clinico San Carlos Madrid
Spain Hospital Ramón y Cajal;Servicio de Neumología Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario de la Princesa; Servicio de Aparato Digestivo Madrid
Spain Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz Madrid
Spain Hospital Clinico Universitario Virgen de la Victoria Malaga
Spain Hospital Univ. Central de Asturias Oviedo Asturias
Spain Corporació Sanitaria Parc Taulí; Servicio de Neurología Sabadell Barcelona
Spain Hospital Clinico Universitario de Salamanca Salamanca
Spain Hospital Universitario Marques de Valdecilla Santander Cantabria
Spain CHUS ? H. Clinico U. de Santiago Santiago de Compostela LA Coruña
Spain Hospital Clinico Universitario de Valencia Valencia
Spain HUA - Txagorritxu Vitoria Alava
Taiwan Buddhist Tzu Chi Dalin General Hospital; Rheumatology Chia-yi
Taiwan Kaohsiung Medical University Hospital; Chung-Ho Memorial Hospital Kaoshiung City
Taiwan China Medical University Hospital Taichung
Taiwan National Cheng Kung University Hospital Tainan
Taiwan Far Eastern Memorial Hospital; Department of Clinical Pathology Taipei
Taiwan National Taiwan University Hospital Taipei
Taiwan Veterans General Hospital - Taichung Xitun Dist.
Turkey Istanbul Universitesi Onkoloji Enstitüsü Hastanesi ?stanbul
Turkey Cukurova Universitesi Tip Fakultesi Balcali Hastanesi; Balcali Adana
Turkey Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Hastanesi Ankara
Turkey Uludag Universitesi - Saglik Uygulama ve Arastirrma Merkezi Bursa
Turkey Gaziantep Universitesi Tip Fakultesi Gaziantep
Turkey Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim ve Arastirma Hastanesi Istanbul
Turkey Dokuz Eylul University Faculty of Medicine; Chest Diseases Izmir
Turkey Ege Universitesi Tip Fakultesi Hastanesi Izmir
Turkey Kocaeli Universitesi Tip Fakultesi Kocaeli
Turkey Marmara Universitesi Hastanesi Marmara University Hospital Maltepe
Turkey Eriyes universitesi T?p Fakultesi Hastanesi Melikgazi/Kayser
Turkey Mersin Universitesi Tip Fakultesi Hastanesi; Tibbi Onkoloji Birimi Mersin
Turkey Akdeniz University Faculty of Medicine Department of Pulmonology Muratpasa/Antalya
Turkey Koc Universitesi (KU) Tip Fakultesi (Koc University School of Medicine) Sariyer
United States University of Alabama at Birmingham Birmingham Alabama
United States Massachusetts General Hospital Boston Massachusetts
United States Meris Clinical Research Brandon Florida
United States Florida Lung, Asthma and Sleep Specialists (FLASS) - Celebration Celebration Florida
United States The Lung Research Center Chesterfield Missouri
United States SleepMed of South Carolina Columbia South Carolina
United States Advanced Pulmonary & Sleep Research Institute of Florida Daytona Beach Florida
United States National Jewish Health Medical Center Denver Colorado
United States NorthShore University HealthSystem Evanston Illinois
United States Inova Fairfax Hospital Falls Church Virginia
United States University of Texas Medical Branch at Galveston Galveston Texas
United States Pulmonix Research Greensboro North Carolina
United States University of Iowa Hospitals and Clinics; Investigational Drug Services Iowa City Iowa
United States University of Florida Health Pulmonology - Jacksonville Jacksonville Florida
United States University of Kansas Medical Center Kansas City Kansas
United States University of Louisville Health Sciences Center Louisville Kentucky
United States Advanced Pulmonary Research Institute Loxahatchee Groves Florida
United States Metroplex Pulmonology & Sleep Center McKinney Texas
United States University of Minnesota Medical Center Minneapolis Minnesota
United States Vanderbilt University Medical Center Nashville Tennessee
United States Yale New Haven Hospital New Haven Connecticut
United States Lenox Hill Hospital New York New York
United States Lowcountry Lung and Critical Care North Charleston South Carolina
United States University of Nebraska Medical Center Omaha Nebraska
United States Jefferson University Physicians (JUP) - Jefferson Pulmonary Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States Virginia Commonwealth University Richmond Virginia
United States Mayo Clinic Rochester Rochester Minnesota
United States University of California Davis Sacramento California
United States Washington University Saint Louis Missouri
United States University Of Utah Hosp & Clin; Investigational Pharmacy Salt Lake City Utah
United States Inst. of Healthcare Assessment, Inc. San Diego California
United States UCSF Medical Center San Francisco California
United States Sarasota County Public Hospital Sarasota Florida
United States Spartanburg Medical Center Spartanburg South Carolina
United States Georgetown University Medical Center Washington District of Columbia
United States Renstar Medical Research Wesley Chapel Florida
United States PMG Research of Wilmington Wilmington North Carolina
United States Florida Pulmonary Research Institute, LLC Winter Park Florida

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Canada,  China,  Czechia,  Denmark,  France,  Germany,  Greece,  Hong Kong,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  New Zealand,  Norway,  Poland,  Portugal,  Singapore,  South Africa,  Spain,  Taiwan,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Adverse Events (AE) Severity will be determined according to the 5-point severity scale (National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 [NCI CTCAE, v.5.0]). From baseline until 8 weeks after the final dose
Primary Percentage of Participants with Infusion Related Reactions (IRRs) and other AEs of Special Interest From baseline until 8 weeks after the final dose
Primary Percentage of of Participants Permanently Discontinuing Study Treatment due to AEs From baseline until 8 weeks after the final dose
Primary Change from Baseline in Targeted Clinical Laboratory Test Results From baseline until 8 weeks after the final dose
Secondary Annual Rate of Change in Forced Vital Capacity (FVC) (mL) From baseline until study completion (up tp 4 years)
Secondary Annual Rate of Change in 6-Minute Walk Distance (6MWD) From baseline until study completion (up tp 4 years)
Secondary Annual Rate of Change in FVC% Predicted From baseline until study completion (up tp 4 years)
Secondary Annual Rate of Change in Carbon Monoxide Diffusing Capacity (DLCO) From baseline until study completion (up tp 4 years)
Secondary Time to Disease Progression Time to first occurrence of >=10% absolute decline in % predicted FVC, >=15% relative decline in 6MWD, or death From the time of randomization until disease progression or death (up tp 4 years)
Secondary Survival Every 6 Months and at study completion (up to 4 years)
Secondary IPF-related Mortality Every 6 Months and at study completion (up to 4 years)
Secondary Respiratory-related Mortality Every 6 Months and at study completion (up to 4 years)
Secondary Plasma Concentrations of PRM-151 at Specified Timepoints Days 1, 3 and 5, Weeks 4, 12 and 24
Secondary Prevalence of Anti-drug Antibodies (ADAs) to PRM-151 at Baseline Baseline (Day 1)
Secondary Percentage of Participants with ADAs During the Study Weeks 4, 12 and 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3
Completed NCT00532233 - SD, IL-13 Production Rate in IPF Phase 2
Completed NCT00540475 - Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry